Home
Syntekabio

Syntekabio Market Share Analysis for August 2026

Syntekabio expands the possibilities of life sciences with AI, data, and supercomputing.

Science and Education > Biology

Domainsyntekabio.com

Year Founded2009

Employees51 - 200

Annual Revenue$2M - $5M

Syntekabio

Syntekabio (including company regionals)

syntekabio.com

See more website traffic and engagement information

Syntekabio Revenue up to August 2026 is 2M - 5M

revenue generated by Syntekabio top domains

Syntekabio top domains revenue over 3 years

Revenue for Syntekabio top domains

syntekabio.com2M - 5M

See more with Sales Intelligence

Total visits to Syntekabio's top domains

Understand Syntekabio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

syntekabio.com2K

See more with Sales Intelligence

Avg. visit duration in Syntekabio's top domains

Analyze Syntekabio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

syntekabio.com00:00:16

See more with Sales Intelligence

Avg. pageviews on Syntekabio's top domains

See how Syntekabio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

syntekabio.com1.29

See more with Sales Intelligence

Syntekabio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Syntekabio

These are the website technologies, by industry, used by Syntekabio top domains

Advertising (3)

DoubleClick

Conversion & Analytics (2)

Google Analytics

Social (2)

Facebook Social Plugins

Audio Video Media (1)

YouTube

More Technologies

5

See all

News & Signals from Syntekabio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSyntekabio, Inc. launched AI-driven Asset Programs on Oct 14th '25.NEW YORK, NY, UNITED STATES, October 20, 2025 /EINPresswire.com/ - AI drug discovery company Syntekabio (KOSDAQ: 226330) announced on October 14 that it has officially launched its AI-driven Asset Programs, aimed at simultaneously identifying antibody and small-molecule drug candidates using the company's proprietary AI supercomputing infrastructure.

NewsMetaVia Inc. partners with Syntekabio, Inc..MetaVia announces ai-driven collaboration with Syntekabio to explore additional indications for DA-1241.

NewsSyntekabio, Inc. attended event 2025 JP Morgan Healthcare Conference on Jan 13th '25.Syntekabio announced that it will participate in the 2025 JP Morgan Healthcare Conference and Biotech Showcase held in San Francisco on Jan. 13 (local time) to showcase its language model software-as-a-service (SaaS) for global pharmaceutical companies and biotech firms.